These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35114188)

  • 1. Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.
    Nakai T; Saigusa D; Iwamura Y; Matsumoto Y; Umeda K; Kato K; Yamaki H; Tomioka Y; Hirano I; Koshiba S; Yamamoto M; Suzuki N
    Biochem Pharmacol; 2022 Mar; 197():114939. PubMed ID: 35114188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
    Katagiri N; Hitomi H; Mae SI; Kotaka M; Lei L; Yamamoto T; Nishiyama A; Osafune K
    Sci Rep; 2021 Feb; 11(1):3936. PubMed ID: 33594180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
    Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1
    Jatho A; Zieseniss A; Brechtel-Curth K; Guo J; Böker KO; Salinas G; Wenger RH; Katschinski DM
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
    Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
    J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells.
    Shih HM; Pan SY; Wu CJ; Chou YH; Chen CY; Chang FC; Chen YT; Chiang WC; Tsai HC; Chen YM; Lin SL
    J Biomed Sci; 2021 Nov; 28(1):73. PubMed ID: 34724959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
    Yasuoka Y; Izumi Y; Fukuyama T; Omiya H; Pham TD; Inoue H; Oshima T; Yamazaki T; Uematsu T; Kobayashi N; Shimada Y; Nagaba Y; Yamashita T; Mukoyama M; Sato Y; Wall SM; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
    Molecules; 2022 Feb; 27(3):. PubMed ID: 35164384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
    Mima A; Horii Y
    In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
    Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
    Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
    Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H; Wang X; Zhang X; Wang H; Jiang W
    Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological induction of the hypoxia response pathway in Huh7 hepatoma cells limits proliferation but increases resilience under metabolic stress.
    Jacquemin C; El Orch W; Diaz O; Lalande A; Aublin-Gex A; Jacolin F; Toesca J; Si-Tahar M; Mathieu C; Lotteau V; Perrin-Cocon L; Vidalain PO
    Cell Mol Life Sci; 2024 Jul; 81(1):320. PubMed ID: 39078527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
    Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
    Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.